Looking for Sentiment Analysis? Discover the most popular stocks on Reddit by using our Sentiment Tracker
Market Cap 89.26M P/E 4.63 EPS this Y 32.60% Ern Qtrly Grth -
Income -9.99M Forward P/E -12.91 EPS next Y 432.30% 50D Avg Chg 7.00%
Sales 19.05M PEG - EPS past 5Y - 200D Avg Chg 13.00%
Dividend N/A Price/Book 2.16 EPS next 5Y - 52W High Chg -35.00%
Recommedations 2.00 Quick Ratio 13.08 Shares Outstanding 24.81M 52W Low Chg 130.00%
Insider Own 7.11% ROA -12.83% Shares Float 23.80M Beta 0.24
Inst Own 15.15% ROE -20.77% Shares Shorted/Prior 1.57M/1.69M Price 4.26
Gross Margin 94.36% Profit Margin -52.42% Avg. Volume 250,806 Target Price 19.20
Oper. Margin -321.05% Earnings Date May 13 Volume 92,561 Change 2.16%
About Ocuphire Pharma, Inc.

Ocuphire Pharma, Inc., a clinical-stage ophthalmic biopharmaceutical company, focuses on developing and commercializing therapies for the treatment of unmet needs of patients with refractive and retinal eye disorders. The company offers Phentolamine Ophthalmic Solution for reversal of mydriasis, as well as is in Phase III clinical trials for presbyopia and dim light or night vision disturbances. Its lead retinal product candidate is APX3330, a small-molecule inhibitor of reduction oxidation effector factor-1 protein that has completed Phase II clinical trial for the treatment of diabetic retinopathy. The company also develops APX2009 and APX2014 that are preclinical product candidates for retina indications. The company was founded in 2018 and is headquartered in Farmington Hills, Michigan.

Ocuphire Pharma, Inc. News
04/11/24 First Patient Enrolled in LYNX-2 Phase 3 Study Evaluating Phentolamine Ophthalmic Solution 0.75% (PS) for the Treatment of Decreased Visual Acuity Under Low Light Conditions Following Keratorefractive Surgery
04/01/24 Ocuphire Announces the U.S. Commercial Launch of RYZUMVl™ (Phentolamine Ophthalmic Solution 0.75%) by its Partner Viatris
03/13/24 Earnings Update: Ocuphire Pharma, Inc. (NASDAQ:OCUP) Just Reported And Analysts Are Trimming Their Forecasts
03/10/24 Ocuphire Pharma Full Year 2023 Earnings: Misses Expectations
03/08/24 Ocuphire Pharma Announces Financial Results for Fourth Quarter and Full Year 2023 and Provides Corporate Update
02/23/24 Ocuphire Pharma to Present in the BIO CEO & Investor Conference
02/15/24 Ocuphire Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
02/14/24 Ocuphire Pharma Strengthens Leadership Team with Key Appointments
02/05/24 Ocuphire Pharma Announces Presentation on APX3330 at the Annual Angiogenesis, Exudation, and Degeneration 2024 Conference
01/04/24 Ocuphire Pharma Receives FDA Agreement Under Special Protocol Assessment for LYNX-2 Phase 3 Trial of Phentolamine Ophthalmic Solution for the Treatment of Decreased Visual Acuity under Dim (mesopic) Light Conditions
11/30/23 Ocuphire Pharma Announces Presentation at Ophthalmology Innovation Summit (OIS) XIII
11/27/23 Ocuphire Pharma Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
11/27/23 Ocuphire Pharma Announces Appointment of Joseph Schachle, M.B.A., as Chief Operating Officer
11/13/23 Ocuphire Pharma Announces Financial Results for Third Quarter 2023 and Provides Corporate Update
11/10/23 Declining Stock and Solid Fundamentals: Is The Market Wrong About Ocuphire Pharma, Inc. (NASDAQ:OCUP)?
11/02/23 Ocuphire Pharma Announces Successful End-of-Phase 2 Meeting with FDA for Oral APX3330 in Diabetic Retinopathy
11/01/23 Ocuphire Pharma Announces Appointment of George Magrath, M.D., M.B.A., M.S., as Chief Executive Officer and Director
10/26/23 Ocuphire Pharma to Present at AAO 2023 and Eyecelerator Retina Showcase
10/06/23 Ocuphire Pharma to Present at Euretina and Retina Society Conferences in October
09/27/23 Viatris and Ocuphire Pharma Announce FDA Approval of RYZUMVl™ (Phentolamine Ophthalmic Solution) 0.75% Eye Drops for the Treatment of Pharmacologically-Induced Mydriasis Produced by Adrenergic Agonists (e.g., Phenylephrine) or Parasympatholytic (e.g., Tropicamide) Agents
OCUP Chatroom

User Image XbrCapital Posted - 4 minutes ago

$OCUP This thing needs PR until the green earnings. Some popular YouTuber needs to pick up on it.

User Image newtraderlookingforhope Posted - 13 minutes ago

$OCUP Purchased 10k at $1.60 as planned. Somehow, if we drop to 30m market cap, which would just be absurd assuming no dilution, I am going to purchase another 10k. Super low risk at this point.

User Image surferbja Posted - 1 hour ago

$OCUP OCUP has No Debt (Buy Low) Market missing OCUP value. OCUP COO and CFO know OCUP is a value buy. Debt/Equity 0.00x Debt/Assets 0.00x 3/21/24 Schachle Joseph K Schachle Joseph K - Chief Operating Officer Chief Operating Officer Purchase 2,000 2.05 – 2.05 2,000 $4.1 K and Jhaveri Nirav Chief Financial Officer Purchase 10,000 2.10 – 2.10 150,000

User Image JoeD32 Posted - 2 hours ago

$OCUP 1.50 closer than it looks 😂 then its on to the next

User Image peterb030 Posted - 2 hours ago

$OCUP mail nr 6 and their contact form on their site, still being polite..... who knows

User Image Lskynrd1 Posted - 4 hours ago

$OCUP I'm new at this what is the SPA and it's relevance to the FDA, appreciate any help

User Image XbrCapital Posted - 7 hours ago

$OCUP any chance we’ll see green earnings on 03 May?

User Image JussieLivermore Posted - 23 hours ago

$OCUP A year ago tomorrow a "wise" group of people gathered together and decided to fire the CEO of OCUP. The stock was trading at $6.50 at the time. Since that time, all the fine work Mina and team had invested in the company has paid off in terms of COMPANY PROGRESS with the highlight being approval and launch of Ryzumvi. Today, the stock closed at $1.67 despite positive business progress. It is time to replace the board and perhaps the new management team. The market has lost confidence.

User Image TickrTalk0007 Posted - 1 day ago

$OCUP lower lows is not. looks like the SPA is a no go with the fda. mgmt not sharing material information if its a no go

User Image JoeD32 Posted - 1 day ago

$OCUP its better if there is bad news regarding the SPA…would probably shoot it up 20-30 percent 😂

User Image TheAliAbdul Posted - 1 day ago

$OCUP struggling to get passed $1.78 resistance, I need $2.30 to break even now.

User Image Novice1a Posted - 1 day ago

$OCUP

User Image peterb030 Posted - 1 day ago

$OCUP now there is buying 14k 17 k and we're on 1.77 again we want news

User Image peterb030 Posted - 1 day ago

$OCUP all time low 1.69 with only good news

User Image mary46 Posted - 1 day ago

$OCUP stop putting 20 dollar Price target's on a crap stock analyst's

User Image mary46 Posted - 1 day ago

Under a Dollar soon $OCUP

User Image TickrTalk0007 Posted - 1 day ago

$OCUP I look at OCUL‘s A-team in retina and then I look at OCUP’s on-job-training roster and it makes me 😂 congratulations to the retail shareholders who cant do anything but watch this dumpster fire.

User Image JussieLivermore Posted - 1 day ago

$OCUP Not only are they granting Dr. Pepose some equity, but they are also giving him a big monthly consulting fee. Burning cash.

User Image JoeD32 Posted - 2 days ago

$OCUP under 100k in volume toddy seems to be it

User Image Run_Taurus Posted - 2 days ago

$OCUP when did the date of the earnings report change. was going to be in june now one week after vtrs ?

User Image OldManLogan Posted - 2 days ago

$OCUP $VKTX Then I'll have to start shopping for private islands, lol.

User Image XbrCapital Posted - 3 days ago

$OCUP if $VKTX touched 99$ with zero revenue, this should be 200$ by the time the retinopathy molecule hits the pharmacy shelves.

User Image CunningStunt69 Posted - 3 days ago

$OCUP Well I don't like it enough to add any more. Just gonna sit and see what happens I guess. You never know with micro caps, any idiot can jack it around.

User Image JoeD32 Posted - 3 days ago

$OCUP retail seems all tapped out…gonna need some big buys to get her going

User Image peterb030 Posted - 3 days ago

$OCUP no news FDA, so thats gonna be tricky but we learned last week that it could take up to 90 days but not hearing anything from my 2 mails and a lot more from others makes overhere so i,m a little bit more concerned day by day. we had no exact date so we took the last day off february so today should be the day if not then after earnings?

User Image peterb030 Posted - 3 days ago

$OCUP so the 45 days are over so it will be another 45

User Image alexquick123 Posted - 3 days ago

$OCUP

User Image Edge0D Posted - 3 days ago

$OCUP as far as I can tell the COO only owns 2k shares. Is it reasonable to think he will load up before corporate starts trying to pump the price?

User Image Fiercegreen Posted - 3 days ago

$OCUP more leadership acquiring stock. I don't see a lot of selling. It's almost like anyone selling at these prices might be shortsighted. Emphasis on the "short".

User Image JoeD32 Posted - 3 days ago

$OCUP if it tanks to 1.50 I’ll have to bow out

Analyst Ratings
Alliance Global Partners Buy Mar 20, 24
HC Wainwright & Co. Buy Mar 11, 24
HC Wainwright & Co. Buy Nov 14, 23
Cantor Fitzgerald Overweight Aug 14, 23
HC Wainwright & Co. Buy Aug 14, 23
HC Wainwright & Co. Buy May 16, 23
HC Wainwright & Co. Buy Mar 31, 23
HC Wainwright & Co. Buy Feb 17, 23
HC Wainwright & Co. Buy Jan 26, 23
Insider Trades Relationship Date Transactions Cost($) #Shares Value($) #Share Own SEC Form 4
MANUSO JAMES S J Director Director May 20 Buy 1.99 5,000 9,950 21,570 05/24/22